KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Short-Term Debt repayments (2023)

Supernus Pharmaceuticals (SUPN) has disclosed Short-Term Debt repayments for 1 consecutive years, with $78.4 million as the latest value for Q2 2023.

  • On a quarterly basis, Short-Term Debt repayments changed N/A to $78.4 million in Q2 2023 year-over-year; TTM through Mar 2024 was $78.4 million, a 435.38% increase, with the full-year FY2023 number at $93.0 million, changed N/A from a year prior.
  • Short-Term Debt repayments was $78.4 million for Q2 2023 at Supernus Pharmaceuticals, up from $14.6 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $78.4 million in Q2 2023 to a low of $14.6 million in Q1 2023.